ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
63,436.82
-0.88%
S&P 500
5,159.16
0.61%
Dow Jones
38,752.64
0.20%
US Dollar vs Yen
153.904
0.22%
Brent Oil
83.11
-0.02%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Nuvalent Inc (NUVL)

  7. Nuvalent Inc (NUVL) ニュース

NUVL Nuvalent Inc

69.38
-0.97 (-1.38%)
最終更新日： 01:58:04
15分遅延
名称 銘柄コード 市場 種別
Nuvalent Inc NUVL NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
Upgrade Icon
-0.97 -1.38% 69.38 01:58:04
始値 安値 高値 終値 前日終値
69.99 68.79 70.69 70.35
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/0905:30PRNUSNuvalent Presents New Preclinical Data Supporting Profiles..
2024/3/0606:52PRNUSNuvalent to Present New Preclinical Data on HER2-Selective..
2024/2/2721:00EDGAR2Form S-8 - Securities to be offered to employees in employee..
2024/2/2720:42EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/2/2720:38EDGAR2Form 8-K - Current report
2024/2/2720:30PRNUSNuvalent Highlights Pipeline Progress, Reiterates Key..
2024/2/2720:15PRNUSNuvalent Receives U.S. FDA Breakthrough Therapy Designation..
2024/2/1220:30PRNUSNuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical..
2024/2/0120:30PRNUSNuvalent to Participate in the Guggenheim Healthcare Talks..
2024/1/1006:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1006:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1006:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1006:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1006:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1006:40EDGAR2Form 8-K - Current report
2024/1/0820:30PRNUSNuvalent Announces "OnTarget 2026" Operating Plan and Key..
2023/12/2907:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2706:31EDGAR2Form 144 - Report of proposed sale of securities
2023/12/2120:30PRNUSNuvalent to Present at the 42nd Annual J.P. Morgan..
2023/12/2106:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2106:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2106:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2008:00EDGAR2Form 144 - Report of proposed sale of securities
2023/12/1907:45EDGAR2Form 144 - Report of proposed sale of securities
2023/12/1907:32EDGAR2Form 144 - Report of proposed sale of securities
2023/12/1907:23EDGAR2Form 144 - Report of proposed sale of securities
2023/12/0106:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/1420:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/1420:45EDGAR2Form 8-K - Current report
2023/11/1420:30PRNUSNuvalent Highlights Corporate and Pipeline Achievements and..
2023/11/0405:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/0119:30PRNUSNuvalent to Participate in the BMO Virtual BioPharma..
2023/10/2705:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/2507:01EDGAR2Form 144 - Report of proposed sale of securities
2023/10/1805:07EDGAR2Form 8-K - Current report
2023/10/1805:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2023/10/1710:55PRNUSNuvalent Announces Pricing of Public Offering of Common..
2023/10/1620:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2023/10/1620:30PRNUSNuvalent Announces Public Offering of Common Stock
2023/10/1319:40EDGAR2Form 8-K - Current report
2023/10/1319:30PRNUSNuvalent Reports Preliminary Phase 1 Clinical Data from..
2023/10/0705:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/0705:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/0505:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/0505:12EDGAR2Form 144 - Report of proposed sale of securities
2023/10/0505:05EDGAR2Form 8-K - Current report
2023/10/0501:21PRNUSPreliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial..
2023/9/2005:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/9/1819:30PRNUSNuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2..
2023/9/0705:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..

最近閲覧した銘柄

NASDAQ
NUVL
Nuvalent
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有